title: Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
abstract: BACKGROUND
  This study aimed to evaluate the efficacy of docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
  
  
  METHODS
  We retrospectively analyzed data regarding thirty patients with borderline-resectable T4 tumor who received either DCF or cisplatin plus 5-fluorouracil (FP) as induction chemotherapy.
  
  
  RESULTS
  The overall response rate was significantly better for the DCF group than the FP group. In the DCF group, 6/16 patients achieved a grade 2 histological post-chemotherapeutic effect after treatment, compared to 1/14 in FP group. Except for myelotoxicity, no other significant differences in toxicity were observed during induction chemotherapy between groups. The DCF regimen did not result in increased postoperative complications compared to the FP regimen. Postoperative recurrence or distant metastasis was observed in 7/10 of FP patients and 5/12 of DCF patients.
  
  
  CONCLUSIONS
  DCF induction chemotherapy may be an option for conversion therapy of initially unresectable, locally advanced esophageal cancer.
authors.affiliation: Department of Clinical Oncology, Aichi Cancer Center Hospital, Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. tomoya.yokota@gmail.com
authors.forename: Tomoya
authors.initials: T
authors.lastname: Yokota
authors.forename: Shunzo
authors.initials: S
authors.lastname: Hatooka
authors.forename: Takashi
authors.initials: T
authors.lastname: Ura
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Abe
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahari
authors.forename: Kohei
authors.initials: K
authors.lastname: Shitara
authors.forename: Motoo
authors.initials: M
authors.lastname: Nomura
authors.forename: Chihiro
authors.initials: C
authors.lastname: Kondo
authors.forename: Ayako
authors.initials: A
authors.lastname: Mizota
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yatabe
authors.forename: Masayuki
authors.initials: M
authors.lastname: Shinoda
authors.forename: Kei
authors.initials: K
authors.lastname: Muro
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000209:etiology; D012008:Recurrence; D012189:Retrospective Studies; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil